secwatch.observer — SEC 8-K summary
======================================

Issuer:     STRATA Skin Sciences, Inc. (SSKN)
CIK:        0001051514
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001140361-24-015650
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Strata Skin Sciences Q4 rev $8.7M, net loss $3.8M; FY rev $33.4M, net loss $10.8M
--------------------------------------------------------------------------------

- Q4 2023 revenue $8.7M vs $10.6M in Q4 2022; net loss $3.8M ($0.11 EPS) vs $0.2M loss.
- Full-year 2023 revenue $33.4M vs $36.2M; net loss $10.8M ($0.31 EPS) vs $5.6M loss.
- Recorded $2.3M goodwill impairment in dermatology recurring procedures segment.
- Installed XTRAC base 923 devices; launched TheraClear X acne system with 92 devices in operation.
- Dr. Dolev Rafaeli appointed Vice-Chairman, President and CEO in October 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1051514/000114036124015650/0001140361-24-015650-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1051514/000114036124015650/ef20025035_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-015650

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer